

11 Sep 2025

COR/2025/MY/NEXAQTAB-168(1)

Senior Principal Assistant Director  
Centre of Product & Cosmetic Evaluation  
National Pharmaceutical Regulatory Agency,  
Jalan Universiti,  
46730 Petaling Jaya, Selangor.

**(U/P: Pn Balqis)**

Dear Puan,





**Justification for the ink colour for Aluminium Foil**

Product	Active Ingredient(s)
NEXAQ FILM-COATED TABLETS 5MG	Apixaban 5mg
NEXAQ FILM-COATED TABLETS 2.5MG	Apixaban 2.5mg

With reference to the application for the new registration of the above-mentioned product, please note that NexaQ Film-Coated Tablet 5 mg and NexaQ Film-Coated Tablet 2.5 mg are distinguished by colour, size, and shape, which enable healthcare providers to easily identify the products through the clear PVC/PVdC-aluminium blister packaging.

In addition, to further differentiate the two strengths, the aluminium foil label designs have been intentionally made distinct. Furthermore, the blister label for NexaQ Film-Coated Tablets 2.5 mg is printed in a horizontal layout, while the blister label for NexaQ Film-Coated Tablets 5 mg is printed in a vertical layout. Each blister pocket of the product carries the product name, active ingredient, and strength.

We have the limitation to change the blister printing colour as the printing is the on-line machine printing where "blue" is the only colour installed in the production line. Pre-printed foil is not used because it is not compatible with our production machine. Nevertheless, the use of single ink colour will not cause any risk of mix-up during Xepa's manufacturing process or during dispensing of these medicines by healthcare providers, owing to the product differentiation described above.

NexaQ Film-Coated Tablet 5mg	NexaQ Film-Coated Tablet 2.5mg
	
	

Thank you.

Yours sincerely,  
**XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD**



Lim Hui Kheng  
 Assistant Regulatory Affairs Manager